Clinical Trial Update: Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated subcutaneous amifostine (Ethyol) for preventing radiochemotherapy-induced esophagitis and pneumonitis in patients with unresectable no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagitis
• Non-small Cell Lung Cancer
• Pneumonitis

Drugs mentioned

• ETHYOL (Amifostine)

Snippet

Sponsor: MedImmune LLC | Conditions: Esophagitis, Pneumonitis | Phase 2 | Status: COMPLETED